Promega has partnered with BioIVT, a provider of research models and services for drug and diagnostic development, the company announced today.

According to a release, BioIVT will offer Promega Immune Checkpoint and antibody-dependent cell-mediated cytotoxicity (ADCC) Reporter Bioassays to support immunology and immuno-oncology research.

“We are excited to team up with BioIVT to help advance immunology and immuno-oncology research,” Promega Vice President of Life Sciences Thomas Livelli said in a statement. “BioIVT shares our commitment to high-quality data and excellent customer service, and it has also demonstrated the ability to create new, cutting-edge assays.”

The two companies look to expand their partnership to include additional products and services in the future.